MetaCap

Ernexa Therapeutics (ERNA) vs 60 Degrees Pharmaceuticals (SXTP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ernexa Therapeutics is the larger company by market cap ($2.3 million vs $2.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ERNA-43.10%SXTP-57.44%
+7%-27%-61%
Oct 7, 20261 yearNov 20, 2026
ERNA-43.33%SXTP-51.50%
+3%-26%-54%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ERNA versus SXTP key metrics
MetricERNASXTP
Share price$1.36$0.4682
Market cap$2.30M$2.10M
1-day change-16.56%-6.36%
EPS (TTM)$-11.22$-5.34
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.01M
Revenue growth (YoY)—+65.49%
Net income (latest FY)$-14.08M$-7.37M
Gross margin—22.26%
Operating margin—-771.64%
Net margin—-732.51%
52-week high$37.50$8.62
52-week low$1.35$0.46
Distance from 52-week high-96.37%-94.57%
Analyst consensusnonenone
Avg. price target upside+2105.88%+690.26%
Average volume43.90K407.29K
Shares outstanding1.69M4.48M
Employees53
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ernexa Therapeutics

ERNA stock →

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About 60 Degrees Pharmaceuticals

SXTP stock →

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

ERNA vs SXTP FAQ

Which is bigger, Ernexa Therapeutics or 60 Degrees Pharmaceuticals?

Ernexa Therapeutics (ERNA) is larger, with a market capitalization of $2.30M compared with $2.10M for 60 Degrees Pharmaceuticals (SXTP).

Are Ernexa Therapeutics and 60 Degrees Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons